Oramed Pharmaceuticals Inc

Oramed Pharmaceuticals Inc. is a biotechnology company focused on research and development of pharmaceutical solutions, using a technology platform for oral delivery of therapeutic proteins. Its lead candidate, ORMD-0801, is an oral insulin capsule in Phase III clinical trials for the treatment of diabetes. The company also has license agreements with Oravax Medical Inc. for the commercialization of oral COVID-19 vaccines. Incorporated in 2002, Oramed Pharmaceuticals Inc. is headquartered in New York, New York.